Dupixent is available as a solution inside single-dose prefilled pens and syringes, given as a subcutaneous injection. Dupixent is a biologic and belongs to a drug class called interleukin-4 (IL-4 ...

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...

SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

The French drugmaker said it had entered a mandate with an “investment service provider”, with the purchase occurring between ...

Dupixent (dupilumab ... The IL-4 and IL-13 targeting antibody is administered as a subcutaneous injection every other week after an initial loading dose, and can be used with or without topical ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Obviously, Dupixent in COPD has a broader label ... And I think that's not to be underestimated. The sub-q formulation offers a significant advantage in terms of patient and nurse experience.

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

PD and efficacy against DUPIXENT in patients with moderate-to-severe AD, with readout expected in the second half of 2026. APG777 is a novel, subcutaneous half-life extended monoclonal antibody ...

PD and efficacy against DUPIXENT in patients with moderate-to-severe AD, with readout expected in the second half of 2026. APG777 is a novel, subcutaneous half-life extended monoclonal antibody ...

Dupixent’s sales rose 16% year over year ... Novo Nordisk announced encouraging data from a phase Ib/IIa study on subcutaneous amycretin, a novel unimolecular GLP-1 and amylin receptor agonist ...